British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer
Alexandra Taylor, Kathryn Clement, Timothy Hillard, Jenifer Sassarini, Nithya Ratnavelu, Holly Baker‐Rand, Rebecca Bowen, Melanie Davies, Katherine Edey, Andreia Fernandes, Sadaf Ghaem‐Maghami, Nana Gomes, Sarah L. Gray, Eluned Hughes, Anna Hudson, Ranjit Manchanda, Kristyn Manley, Shibani Nicum, Andrew Phillips, Alison Richardson, Jo Morrison
Abstract
These guidelines have been developed jointly by the British Gynaecological Cancer Society and British Menopause Society to provide information for all healthcare professionals managing women treated for gynaecological cancer. Menopausal symptoms can have a significant impact on quality of life for women. Cancer therapies, including surgery, pelvic radiotherapy, chemotherapy and endocrine therapy, can all affect ovarian function. The benefits and risks of using hormone replacement therapy are considered by cancer type with guidance on the type of HRT and optimal time of commencement after cancer treatment. Vaginal estrogens can be very effective for improving urogenital symptoms and are safe for the majority of women, including those for whom systemic HRT is contraindicated with rare exceptions. Alternative options to HRT are reviewed including pharmacological and non-pharmacological approaches.